Key result
In-hospital dapagliflozin and spironolactone in HFrEF linked to an early ~5 ml/min/1.73m2 eGFR drop that stabilizes.
Why the study?
Deferring in-hospital initiation of guideline-recommended medications in HFrEF leaves little chance of outpatient initiation, especially in coexisting CKD, prompting investigation of in-hospital initiation safety of SGLT2i with MRA.
Does in-hospital initiation of dapagliflozin and spironolactone safely affect renal function and potassium levels in patients with HFrEF and CKD 3?
Cohort (n=88)
Does in-hospital initiation of dapagliflozin and spironolactone safely affect renal function and potassium levels in patients with HFrEF and CKD 3?
In-hospital initiation of dapagliflozin and spironolactone in HFrEF patients with CKD 3 is generally safe, causing an expected early but non-progressive drop in eGFR and manageable rates of hyperkalemia.
Answers are grounded in this paper and cite their sources.
Supports cautious in-hospital dapagliflozin-spironolactone initiation in HFrEF with CKD3; hypothesis-generating for renal safety monitoring.
Deferring in-hospital initiation of guideline-recommended medications in HFrEF has a few chances they will be initiated ambulatory, especially in the case of coexisting HFrEF and chronic kidney disease (CKD). The aim was to investigate the safety of in-hospital initiation of SGLT2i with MRA therapy for patients hospitalized for HFrEF and CKD 3. Methods 88 patients with HFrEF (on top of standard therapy ACE-I/ARB, B-blockers) and CKD (baseline eGFR between 30 and 60 ml/min) were included in the study. The potassium (K), creatinine (C), uric acid (UA) levels were estimated at baseline and week 12. After biochemical evaluation, patients started on spironolactone (SP) treatment with a median dose of 20 mg daily (titrated) and dapagliflozin (D) with a dose of 10 mg daily (D+SP). Blood pressure (BP), K, and renal function (RF) were checked at weeks 1 (in-hospital), 2, 4, 6, 8, 12 (ambulatory), and more frequently as necessary. Results After the start of therapy D+SP mean eGFR decreased significantly at week 1 from 51.14±9.18 to 46.26±7.91 ml/min/1.73m2 (P<.0001) and at week 2 to 44.18±6.51 ml/min/1.73m2 (-2.08±1.2; P<.001). At week 4 mean eGFR decreased to 42.73±6.86 ml/min/1.73m2 (-1.45±1.1; P<.05). So, a significant decrease in eGFR was observed only during the first month with no significant decrease at 6 and 12 weeks after the start of therapy. Six patients (8%) experienced a significant decline in RF resulting in temporary withdrawal of SP. At week 2 mean K level increased significantly from 4.56±0.63 to 5.07±0.57 mmol/L (P<.001). At weeks 4, 6, 8 K levels remain stable. At week 12 mean K level decreased significantly compared with week 2 (to 4.92±0.57 mmol/L, P<.05). The incidences of severe hyperkalemia (HK) (K+≥6.0mmol/L) were in three patients < 2 %, and moderate HK (K 5.5–5.9 mmol/L) occurred in ten patients (11 %). Patients who experienced inpatient hyperkalemia had a significantly lower eGFR than patients without episodes of HK (38.70 vs. 55.21 mL/min/1.73 m2; P<.0001). Episodes of HK were predicted by baseline K≥5.0 mmol/L and eGFR≤40 ml/min/1.73m2. Additionally, there was a significant improvement in blood UA (-1,53±0.49 mg/dL, P<.01). By multivariate analysis older age, diabetes, low diastolic BP (<60 mm Hg), eGFR≤40 ml/min/1.73m2 at baseline were associated with decreased RF (0.378, P<.01; 0.632, P<.001; 0.771, P<.0001; 0.397, P<.01; respectively), whereas episodes of HK were predicted by baseline K≥5.0 mmol/L and eGFR≤40 ml/min/1.73m2 (0.785, P<.0001; 0.542, P<.001; respectively). Conclusion Initiation of SGLT2i with MRA in patients hospitalized for HFrEF and CKD 3 was mainly safe although it caused an early drop in eGFR. Importantly, a fall in eGFR was observed during the first month. Concern about the reduction in eGFR should be in older diabetic patients with eGFR≤40 and low diastolic blood pressure. Although hyperkalemia was common, the occurrence of it was predicted by baseline potassium level and eGFR.
No takes yet. Share an insight, caveat, or question.
Obertynska et al. (2024) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) stage 3 (n=88). Dapagliflozin and spironolactone was evaluated on Safety (changes in eGFR and potassium levels). In-hospital initiation of dapagliflozin and spironolactone in HFrEF and CKD 3 caused an early eGFR drop at week 1 that stabilized by 12 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: